AKTX
Akari TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade D from latest DB weights. Momentum 37.5 / Value 41.9
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
38
Value
42
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $1.50
Why
Momentum38 · Δ7d -
Value42 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
38
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 37.5 / Value 41.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$16.75M
Beta
0.36
Shares Out
24.29B
P/E (TTM)
-
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.00
Rev YoY
-
EPS YoY
+16.7%
Gross Margin
-
Op Margin
-
Net Debt
$661K
Current Ratio
0.19
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology